Abstract
Drug metabolizing enzymes are of paramount importance in drug detoxification as well as chemical mutagenesis, carcinogenesis and toxicity mediated via metabolic activation. Thus genetically determined differences in the activity of these enzymes can influence individual susceptibility to adverse drug reactions, drug induced diseases and certain types of chemically induced cancers. The genetic polymorphisms of three human drug metabolising enzymes, namely N-acetyltransferase and two cytochrome P450 isozymes (P-450IID6: debrisoquine / sparteine polymorphism, P-450IIC10: mephenytoin polymorphism) have been firmly established. Based on the metabolic handling of certain probe drugs the population can be divided into two phenotypes: the rapid acetylator / extensive metabolizer and slow acetylator / poor metabolizer. These polymorphisms have provided useful tools for the study of the relationship between genetically determined differences in the activity of drug metabolizing enzymes and the risk of adverse drug reactions and certain types of chemically induced diseases and cancers.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Al-Dabbagh, S.A., Idle, J.R. and Smith, R.L. (1981). Animal modelling of human polymorphic drug oxidation -the metabolism of debrisoquine and phenacetin in rat inbred strains. J. Pharm. Pharmacol. 33: 161–164.
Anders, H.H. and Weber W.W. (1986). N-Acetylation pharmacogenetics: Michaelis Menten constants for arylamine drugs as predictors of their N-acetylation rates in vivo. Drug Metab. Dispos. 14: 382–385.
Barbeau, A., Cloutier, T., Roy M., Plasse, L., Paris, S. and Poirier, J. (1985). Ecogenetics of Parkinson’s disease: 4-hydroxylation of debrisoquine. Lancet ii: 1213–1215.
Barbeau, A., Roy, M., Cloutier, T., Plasse, L. and Paris, S. (1986). Environmental and genetic factors in the etiology of Parkinson’s disease. Adv. Neurol. 45: 299–306.
Biehl, J.P. (1957). Emergence of drug resistance as related to the dosage and metabolism of isoniazid. Trans 16th Conf Chemother Tuberc Washington D.C. US Veterans Adm. Army Navy, 108–113.
Bönicke, R. and Reif, W. (1953). Enzymatische Inaktivierung von Isonicotinsäurehydrazid im menschlichen und tierischen Organismus. Arch. Exp. Pathol. Pharmakol. 220: 321–333.
Brosen, K. and Gram, L.F. (1989). Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur. J. Clin. Pharmacol. 36: 537–547.
Caporaso, N., Hayes, R.B., Dosemeci, M., Hoover, R., Ayesh, R., Hetzel, M. Nadidle, J. (1989). Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype. Can. Res. 49: 3675–3679.
Chen, Z.R., Somogyi, A.A. and Bochner, F. (1988). Polymorphic 0-demethylation of codeine. Lancet ii: 914–915.
Cooper, R.G., Evans, D.A.P. and Whibley, E.J. (1984). Polymorphic hydroxylation of perhexiline maleate in man. J. Med. Genet. 21: 27–33.
Dayer, P., Desmeules, J., Leemann, T. and Striberni, R. (1988). Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl./bun). Biochem. Biophys. Res. Commun. 152: 411–416.
Desmeules, J., Dayer, P., Gascon, M.-P. and Magistris, M. (1989). Impact of genetic and environmental factors on codeine analgesia. Clin. Pharmacol. Ther. 45: 122.
Devadatta, S., Gangadharan, P.R.J., Andrews, R.H., Fox, W., Ramakrishnan, C.V., Selhon, J.B. and Veru, S. (1960). Peripheral neuritis due to isoniazid. Bull World Health Org. 23: 587–598.
Drayer, D.E. and Reidenberg, D.M. (1977). Clinical consequences of polymorphic acetylation of basic drugs. Clin. Pharmacol. Ther. 22: 251–258.
Eichelbaum, M. (1975). Ein neuentdeckter Defekt im Arzneimittelstoffwechsel des Menschen: Die fehlende N-Oxidation des Spartein. Habilitationsschrift. Medizinische Fakultät Rheinischen Friedrich-Wilhelms-Universität Bonn.
Eichelbaum, M. and Gross, A.S. (1990). The genetic polymorphism of debrisoquine/sparteine - clinical aspects. Pharmacol. Ther. In press.
Eichelbaum, M., Spannbrucker, N., Steincke, B. and Dengler, H.J. (1979). Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur. J. Clin. Pharmacol. 16: 183–187.
Eichelbaum, M., Bertilsson, L., Uwe, J. and Zekorn, C. (1982a). Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities. Clin. Pharmacol. Ther. 31: 184–186.
Eichelbaum, M., Musch, E., Castro-Parra, M. and v. Sassen, W. (1982b). Isoniazid hepatotoxicity in relation to acetylator phenotype and isoniazid metabolism. Br J. Clin. Pharmacol. 14: 575P - 576 P.
Eichelbaum, M., Baur, M.P., Dengler, H.J., Osikowska-Evers, B.O., Tieves, G., Zekorn, C. and Rittner, C. (1987). Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br J. Clin. Pharmacol. 23: 455–458.
Fonne-Pfister, R., Bargetzi, M.J. and Meyer, U.A. (1987). MPTP, the neurotoxin inducing Parkinson’s disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufl, P450dbl) catalyzing debrisoquine 4- hydroxylation. Biochem. Biophys. Res. Comm. 148: 1144–1150.
Fonne-Pfister, R. and Meyer, U.A. (1988). Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism. Biochem. Pharmacol. 37: 3829–3835.
Ged, C., Umbenauer, D.R., Bellew, T.M., Bork, R.W., Srivastava, P.K., Shinriki, N., Lloyd,R.S. and Guengerich, F.P. (1988). Characterization of cDNAs, mRNAs and proteins related to human liver microsomal cytochrome P-450 S-mephenytoin 4-hydroxylase. Biochemistry 27: 6929–6940.
Gonzalez, F.J. (1989). The molecular biology of cytochrome P-450s. PharmacoL Rev. 40: 243–288.
Gonzalez, F.J., Vilbois, F., Hardwick, J.P., McBride, O.W., Nebert, D.W., Gelboin, H.V. and Meyer, U.A. (1988a). Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics 2: 174–179.
Gonzalez, F.J., Skoda, R.C., Kimura, S., Umeno, M., Zanger, U.M., Nebert, D.W., Gelboin, H.V., Hardwick, J.P. and Meyer, U.A. (1988b). Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (Lond) 331: 442–446.
Grant, D.M., Tang, B.K. and Kalow, W. (1984). Polymorphic N-acetylation of a caffeine metabolite. Clin. Pharmacol. Ther. 33: 355–359.
Grant, D.M., Lottspeich, F. and Meyer, U.A. (1989a). Evidence for two closely related isozymes of arylamine N-acetyltransferase in human liver. FEBS Letters 244: 203–207.
Grant, D.M., Eichelbaum, M. and Meyer, U.A. (1989b). Genetic polymorphism of Nacetyltransferase: enzyme activity and content in liver biopsies correlates with acetylator phenotype determined with caffeine. Eur. J. Clin. Pharmacol. 36: 199.
Grant, D.M., Blum, M., Demierre, A. and Meyer, U.A. (1989c). Nucleotide sequence for an intronless gene for a human arylamine N-acetyltransferases related to polymorphic drug acetylation. Nucleic Acids Res. 17: 3978.
Gut, J., Meyer, U.T., Catin, T. and Meyer, U.A. (1986). Mephenytoin type polymorphism in drug oxidation: purification and characterization of a human liver cytochrome P-450 isozyme catalyzing microsomal mephenytoin hydroxylation. Biochem. Biophys. Acta. 884: 435–447.
Hall, S.D., Guengerich, F.P., Branch, R.A. and Wilkinson, G.A. (1987). Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. J. Pharmacol. Exp. Ther. 240: 216–222.
Horai, Y., Fujita, K. and Ishizaki, T. (1989). Genetically determined N-acetylation and oxidation capacities in Japanese patients with non occupational urinary bladder cancer. Eur. J. Clin. Pharmacol. 37: 581–587.
Hughes, H.B., Schmidt, L.H. and Biehl, J.P. (1955). The metabolism of isoniazid, its implications in therapeutic use. Trans. 14th Conf. Chemother. Tuberc. Washington D.C., U.S. Veterans Adm Army Navy, 217–222.
Inaba, T., Jurima, M. and Kalow, W. (1986). Family studies of mephenytoin hydroxylation deficiency. Am. J. Hum. Genet. 38: 768–772.
Inaba, T., Jorge, L.F. and Arias, T.D. (1988). Mephenytoin hydroxylation in the Cuna Indians of Panama. Brit. J. Clin. Pharmacol. 25: 75–79.
Iselius, L. and Price Evans, D.A.P. (1983). Formal genetics of isoniazid metabolism in man. Clin. Pharmacokin. 8: 541–544.
Jenne, J.W. (1965). Partial purification and properties of the isoniazid transacetylase in human liver: Its relationship to the acetylation of p-amino-salicylic acid. J. Clin. Invest. 44: 1992–2002.
Kaisary, A., Smith, P., Jaczq, E., McAllister, B., Wilkinson,G.R., Ray, W.A. and Branch, R.A. (1987). Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Can. Res. 47: 5488–5493.
Knodell, R.G., Dubey, R.K., Wilkinson, G.R. and Guengerich, F.P. (1988). Oxidative metabolism in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. J. Pharamcol. Exp. Ther. 245: 845–849.
Kroemer, H.K., Mikus, G., Kronbach, T., Meyer, U.A. and Eichelbaum, M. (1989). In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin. Pharmacol. Ther. 45: 28–33.
Kupfer, A. and Preisig, R. (1984). Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. Eur. J. Clin. Pharmacol. 26: 753–759.
Kupfer, A. and Branch, R.A. (1985). Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin. Pharmacol. Ther. 38: 414–418.
Kupfer, A., Desmond, P.V., Schenker, S. and Branch, R.A. (1984). Mephenytoin hydroxylation deficiency: kinetics after repeated doses. Clin Pharmacol Ther 35: 33–39.
Mahgoub, A., Idle, J.R., Dring, L.G., Lancaster, R. and Smith, R.L. (1977). Polymorphic hydroxylation of debrisoquine in man. Lancet ii, 584–586.
McQueen, E.G. (1980). Pharmacological bases of adverse drug reactions. In Drug Treatment, ed Avery G.S., 2nd edn, pp 202–235 Auckland: Adis Press.
Meehan, R.R., Gosden, J.R., Rout, D., Hastie, N.D., Friedberg, T., Adesnik, M., Buckland, R., van Heyningen, V., Fletcher, J., Spurr, N.K., Sweeney, J. and Wolf, C.R. (1988). Human cytochrome P450 PB- 1: a multigene family involved in mephenytoin and steroid oxidation that maps to chromosome 10. Am. J. Hum. Genet. 42: 26–37.
Meier, U.T., Dayer, P., Male, P.J., Kronbach, T. and Meyer, U.A. (1985). Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo. Clin. Pharmacol. Ther. 38: 488–494.
Meier, U.T. and Meyer, U.A. (1987). Genetic polymorphism of human cytochrome P-450 (S) mephenytoin 4-hydroxylase. Studies with human autoantibodies suggest a functionally altered P-450 isozyme as cause of genetic deficiency. Biochemistry 26: 8466–8474.
Meyer, U.A., Skoda, R.C. & Zanger, U.M. (1990). The genetic polymorphism of debrisoquine/sparteine metabolism - molecular mechanisms. Pharmacol Ther,In press.
Mitchell, R.S. & Bell, J.C. (1957). Clinical implications of isoniazide PAS and streptomycin blood levels in pulmonary tuberculosis. Trans Am Clin Clim Ass 69: 98–105.
Mitchell, J.R., Thorgeirsson, U.P., Black, M., Timbrell, J.A., Snodgrass, W.R., Potter, W.Z., Jollow, D.J. & Keiser, H.R. (1975). Increased incidence of isoniazid hepatitis in rapid acetylators: Possible relation to hydrazine metabolites. Clin Pharmacol Ther 18: 70–79.
Musch, E., Eichelbaum, M., Wang, J.K.V., Sassen, W., Castro-Parra, M. ac Dengler, H.J. (1982). Die Häufigkeit hepatotoxischer Nebenwirkungen der tuberkulostatischen Kombinationstherapie (INH, RMP, EMB) in Abhängigkeit vom Acetyliererphänotyp. Klin Wochenschr 60: 513–519.
Nakamura, K., Goto, F., Ray W.A., McAllister, C.B., Jacqz, E. Wilkinson, G.R. & Branch, R.A. (1985). Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38: 402–408.
Newton, B.W., Benson, R.C. & McCarriston, C.C. (1966). Sparteine sulphate: A potent capricious oxytocic. Am J Obstet Gynecol 94: 234–241.
Platzer, R., Kiipfer, A., Bircher, J. & Preisig, R. (1978). Polymorphic acetylation and aminopyrine demethylation in Gilbert’s syndrome. Eur J Clin Invest 8: 219–223.
Price Evans, D.A. (1989). N-Acetyltransferase. Pharmacol Ther 42: 157–234.
Price Evans, D.A. & White, T.A. (1964). Human acetylation polymorphism. J Lab Clin Med 63: 394–403.
Price Evans, D.A., Manley, K.A. & Mc Kusick, V.A. (1960). Genetic control of isoniazid metabolism in man. Br Med J 2: 485–461.
Price Evans,D.A., Mahgoub, A., Sloan, T.P., Idle, J.R. & Smith, R.L. (1980). A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102–105.
Price Evans, D.A., Eze, L.C. & Whibley, E.J. (1983). The association of the slow acetylator phenotype with bladder cancer. J Med Gen 20: 321–329.
Price Evans, D.A., Paterson, S., Francisco, P. & Alvarez, G. (1985). The acetylator phenotypes of Saudi Arabian diabetics. J Med Genet 22: 479–483.
Raghuram, T.C., Koshakji, R.P., Wilkinson, G.R. & Wood, A.J.J. (1984). Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade. Clin Pharmacol Ther 36: 51–56.
Rao, K.V.N., Mitchison, D.A., Nair, N.G.K., Prema, K. & Tripathy, S.P. (1970). Sulfadimidine acetylation test for classification of patients as slow or rapid inactivators of isoniazide. Br Med J 3: 495–497.
Robitzek, E.H., Selikoff, I.J. & Ornstein, G.G. (1952). Chemotherapy of human tuberculosis with hydrazine derivatives of isonicotinic acid. Q Bull Sea View Hosp N.Y. 13: 27–51.
Sanz, E.J., Villen, T., Alm, C. & Bertilsson, L. (1989). S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquine. Clin Pharmacol Ther 45: 495–499.
Shah, R.R., Oates, N., Idle, J.R., Smith, R.L. & Lockhart, J.D. (1982). Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J 284: 295–299.
Shimada, T., Misono, K.S. & Guengerich, F.P. (1986). Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism: purification and characterization of two similar forms involved in the reaction. J Biol Chem 261: 909–921.
Siddoway, L.A., Thompson, K.A., McAllister, C.B., Wang, T., Wilkinson, G.R., Roden, D.M. & Woosley, R.L. (1987). Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 75: 785–791.
Skoda, R., Gonzalez, F.J., Demierre, A. & Meyer, U.A. (1988). Two mutant alleles of the human cytochrome P 450 dbl gene (P 450 IID1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci 85: 5240–5243.
Sommers, De K., Moncrieff, J. & Avenant, J. (1988). Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of Southern Africa. Human Toxicol 7: 273–276.
Umbenauer, D.R., Martin, M.V., Lloyd, R.S. & Guengerich, F.P. (1987). Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P-450S- mephenytoin 4-hydroxylase. Biochemistry 26: 1094–1099.
Ward, S.A., Walle, T., Walle, U.K., Wilkinson, G.R. & Branch, R.A. (1989). Propranolol’s metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 45: 72–79.
Wedlund, P.J., Aslanian, W.S., McAllister, C.B., Wilkinson, G.R. & Branch, R.A. (1984). Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 36: 773–780.
Wedlund, P.J., Aslanian, W.S., Jacgz, E., McAllister, C.B., Branch, R.A. & Wilkinson, G.R. (1985). Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J Pharmacol Exp Ther 234: 662–669.
Wilkinson, G.R., Guengerich, F.P. & Branch, R.A. (1989). Genetic polymorphism of Smephenytoin hydroxylation. Pharmacol Ther 43: 53–76.
Woosley, R.L., Drayer, D.E., Reidenberg, M.M., Nies, A.S., Carr, K. & Oates, J.A. (1978). Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. New Eng1 J Med 298: 1157–1159.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Plenum Press, New York
About this chapter
Cite this chapter
Gross, A.S., Kroemer, H.K., Eichelbaum, M. (1991). Genetic Polymorphism of Drug Metabolism in Humans. In: Witmer, C.M., Snyder, R.R., Jollow, D.J., Kalf, G.F., Kocsis, J.J., Sipes, I.G. (eds) Biological Reactive Intermediates IV. Advances in Experimental Medicine and Biology, vol 283. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5877-0_79
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5877-0_79
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5879-4
Online ISBN: 978-1-4684-5877-0
eBook Packages: Springer Book Archive